


All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan



AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA142)

NICE GUIDANCE ISSUED MAY 2008

(Refer to NICE website for full guidance on NICE recommendations,
including any specific restrictions on the use of the technology)

Epoetin alfa (Eprex[®])

**For the treatment of anaemia and reduction of
transfusion requirements in adult patients receiving
chemotherapy for solid tumours, malignant lymphoma
or multiple myeloma, and at risk of transfusion as
assessed by the patient's general status**

Janssen-Cilag Ltd

March 2004

Epoetin alfa (Eprex[®]) is indicated for the treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).

AWMSG appraised epoetin alfa (Eprex[®]) during the December 2003 meeting and the decision was not to support the use of erythropoietin in the treatment of anaemia associated with cancer due to the lack of evidence of cost-effectiveness.

[See AWMSG December 2003 meeting minutes for further information.](#)